CAN
vs
S
S&P/ASX 300
CAN
Over the past 12 months, CAN has underperformed S&P/ASX 300, delivering a return of -76% compared to the S&P/ASX 300's +7% growth.
Stocks Performance
CAN vs S&P/ASX 300
Performance Gap
CAN vs S&P/ASX 300
Performance By Year
CAN vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cann Group Ltd
Glance View
Cann Group Ltd. operates research and development and cultivation facilities to grow medicinal cannabis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-05-04. The firm has established research and cultivation facilities in Melbourne and is developing a cultivation facility near Mildura, Victoria. The company focuses on developing and supplying cannabis, cannabis resin and medicinal cannabis products into the Australian market. The firm has a cannabis research license and cannabis cultivation license. The cannabis cultivation license allows the Company to produce Australian grown material that can be prescribed for patient use. The company focuses on plant genetics, breeding, cultivation, extraction, analysis and production techniques to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions.